MA28900B1 - Composes et compositions en tant que modulateurs ppar - Google Patents
Composes et compositions en tant que modulateurs pparInfo
- Publication number
- MA28900B1 MA28900B1 MA29525A MA29525A MA28900B1 MA 28900 B1 MA28900 B1 MA 28900B1 MA 29525 A MA29525 A MA 29525A MA 29525 A MA29525 A MA 29525A MA 28900 B1 MA28900 B1 MA 28900B1
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- compounds
- ppar modulators
- ppar
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57413704P | 2004-05-24 | 2004-05-24 | |
US64967105P | 2005-02-02 | 2005-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28900B1 true MA28900B1 (fr) | 2007-10-01 |
Family
ID=35450825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29525A MA28900B1 (fr) | 2004-05-24 | 2006-12-12 | Composes et compositions en tant que modulateurs ppar |
Country Status (17)
Country | Link |
---|---|
US (1) | US20070244130A1 (fr) |
EP (1) | EP1749003A4 (fr) |
JP (1) | JP2008500354A (fr) |
KR (1) | KR20070043705A (fr) |
AR (1) | AR049186A1 (fr) |
AU (2) | AU2005247930B2 (fr) |
BR (1) | BRPI0511527A (fr) |
CA (1) | CA2563819A1 (fr) |
EC (1) | ECSP067019A (fr) |
IL (1) | IL179375A0 (fr) |
MA (1) | MA28900B1 (fr) |
MX (1) | MXPA06013589A (fr) |
NO (1) | NO20065983L (fr) |
PE (1) | PE20060362A1 (fr) |
RU (1) | RU2412175C2 (fr) |
TW (1) | TW200600505A (fr) |
WO (1) | WO2005116016A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009513633A (ja) * | 2005-10-25 | 2009-04-02 | メルク エンド カムパニー インコーポレーテッド | 糖尿病および高血圧を治療するためのジペプチジルペプチダーゼ−4インヒビターと降圧薬との組合せ |
CA2626446A1 (fr) * | 2005-11-07 | 2007-05-18 | Irm Llc | Composes et compositions utilises en tant que modulateurs des ppar |
JP5175866B2 (ja) * | 2007-02-22 | 2013-04-03 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Gタンパク質共役受容体を調節するための化合物および方法 |
EP1972335A1 (fr) * | 2007-03-23 | 2008-09-24 | Krka | Formes de dosage solide comportant de l'aliskiren et ses sels pharmaceutiques acceptables |
KR100860561B1 (ko) * | 2007-05-02 | 2008-09-26 | 경희대학교 산학협력단 | 컴파운드 k 및 메트포민을 유효성분으로 포함하는당뇨병의 예방 및 치료용 약학적 조성물 |
WO2010045416A2 (fr) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Polytherapies pour le traitement de l'obesite |
WO2010045563A2 (fr) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Thérapies de combinaison pour le traitement de l'obésité |
WO2010045417A2 (fr) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Polytherapies pour le traitement de l'obesite |
US20100113581A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100331419A1 (en) * | 2009-06-25 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20100331420A1 (en) * | 2009-06-26 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20100331999A1 (en) * | 2009-06-29 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20110015663A1 (en) * | 2009-07-17 | 2011-01-20 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
WO2011016469A1 (fr) * | 2009-08-05 | 2011-02-10 | 第一三共株式会社 | Dérivé d'amide |
TWI452045B (zh) * | 2009-08-05 | 2014-09-11 | Daiichi Sankyo Co Ltd | 碸衍生物 |
US20110082407A1 (en) * | 2009-10-01 | 2011-04-07 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN103724289B (zh) * | 2013-12-23 | 2015-08-19 | 同济大学 | (e)-2,4,5-三取代-(1-丙烯基)噁唑环类化合物及合成方法和应用 |
CN104402839B (zh) * | 2014-10-20 | 2016-11-02 | 同济大学 | 一种(e)-2,4,5-三取代-(1-丙烯基)噁唑环类化合物及其制备方法 |
CN108760940A (zh) * | 2018-08-03 | 2018-11-06 | 安徽省金楠医疗科技有限公司 | 一种硫酸氢氯吡格雷检测方法 |
CN112521384B (zh) * | 2021-01-13 | 2021-11-02 | 湖北大学 | 溶剂热一锅法合成苯并噻嗪并环戊二烯衍生物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4325959A (en) * | 1979-08-09 | 1982-04-20 | The Dow Chemical Company | Hypoglycemic 4-(((1,3,4, thiadiazolyl)thio)methyl)benzoic acids, ester and amides |
JPH0662590B2 (ja) * | 1986-09-19 | 1994-08-17 | 久光製薬株式会社 | 新規なベンズオキサゾ−ル誘導体 |
IT1229491B (it) * | 1988-12-28 | 1991-09-03 | Roussel Maestretti S P A Ora R | Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali |
NZ236474A (en) * | 1989-12-20 | 1993-07-27 | Bristol Myers Squibb Co | 4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof |
US5262540A (en) * | 1989-12-20 | 1993-11-16 | Bristol-Myers Squibb Company | [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters |
IT1248528B (it) * | 1991-06-21 | 1995-01-19 | Pierrel Spa | Derivati di eteri e tioeteri (etero) aromatici aventi attivita` antiiperlipidemica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. |
JPH06206805A (ja) * | 1992-02-17 | 1994-07-26 | Hisamitsu Pharmaceut Co Inc | チロシナーゼ阻害剤及びそれを用いた皮膚外用剤 |
US5380738A (en) * | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
JPH11147881A (ja) * | 1997-08-21 | 1999-06-02 | Sankyo Co Ltd | ジヒドロベンゾキノン骨格を有する除草性アゾール誘導体 |
JP2002348281A (ja) * | 2001-03-23 | 2002-12-04 | Takeda Chem Ind Ltd | 5員複素環アルカン酸誘導体 |
-
2005
- 2005-05-20 PE PE2005000563A patent/PE20060362A1/es not_active Application Discontinuation
- 2005-05-23 AR ARP050102114A patent/AR049186A1/es unknown
- 2005-05-23 TW TW094116634A patent/TW200600505A/zh unknown
- 2005-05-24 CA CA002563819A patent/CA2563819A1/fr not_active Abandoned
- 2005-05-24 EP EP05775612A patent/EP1749003A4/fr not_active Withdrawn
- 2005-05-24 US US11/597,260 patent/US20070244130A1/en not_active Abandoned
- 2005-05-24 BR BRPI0511527-2A patent/BRPI0511527A/pt not_active IP Right Cessation
- 2005-05-24 AU AU2005247930A patent/AU2005247930B2/en not_active Ceased
- 2005-05-24 KR KR1020067024605A patent/KR20070043705A/ko not_active Application Discontinuation
- 2005-05-24 WO PCT/US2005/018166 patent/WO2005116016A1/fr active Application Filing
- 2005-05-24 JP JP2007515254A patent/JP2008500354A/ja active Pending
- 2005-05-24 RU RU2006145893/04A patent/RU2412175C2/ru not_active IP Right Cessation
- 2005-05-24 MX MXPA06013589A patent/MXPA06013589A/es not_active Application Discontinuation
-
2006
- 2006-11-16 IL IL179375A patent/IL179375A0/en unknown
- 2006-11-21 EC EC2006007019A patent/ECSP067019A/es unknown
- 2006-12-12 MA MA29525A patent/MA28900B1/fr unknown
- 2006-12-22 NO NO20065983A patent/NO20065983L/no not_active Application Discontinuation
-
2009
- 2009-07-01 AU AU2009202673A patent/AU2009202673A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ECSP067019A (es) | 2006-12-29 |
AU2005247930A1 (en) | 2005-12-08 |
PE20060362A1 (es) | 2006-05-15 |
TW200600505A (en) | 2006-01-01 |
RU2412175C2 (ru) | 2011-02-20 |
KR20070043705A (ko) | 2007-04-25 |
JP2008500354A (ja) | 2008-01-10 |
AU2009202673A1 (en) | 2009-07-23 |
US20070244130A1 (en) | 2007-10-18 |
BRPI0511527A (pt) | 2008-01-02 |
EP1749003A1 (fr) | 2007-02-07 |
RU2006145893A (ru) | 2008-06-27 |
NO20065983L (no) | 2007-02-05 |
CA2563819A1 (fr) | 2005-12-08 |
WO2005116016A1 (fr) | 2005-12-08 |
EP1749003A4 (fr) | 2010-05-05 |
AU2005247930B2 (en) | 2009-04-02 |
AR049186A1 (es) | 2006-07-05 |
IL179375A0 (en) | 2007-03-08 |
MXPA06013589A (es) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28900B1 (fr) | Composes et compositions en tant que modulateurs ppar | |
LTC2548560I2 (lt) | Kompozicijos ir būdai, skirti SMN2 splaisingo moduliavimui | |
MX2008007976A (es) | Composiciones colorantes | |
IL179376A0 (en) | Compounds and compositions as ppar modulators | |
DK2069335T3 (da) | Pyridin-3-ylderivater som immunomoduleringsmidler | |
EP1745027A4 (fr) | Composes et compositions en tant que modulateurs de ppar | |
DE602007002929D1 (de) | Lichtempfindliche Zusammensetzung | |
EP1756062A4 (fr) | Composés et compositions servant de modulateurs de ppar | |
DE602006006369D1 (de) | Entwicklerzusammensetzungen | |
MA28563B1 (fr) | 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation | |
DK1967534T3 (da) | Klæbende sammensætning | |
BRPI0813230A2 (pt) | Moduladores de calicreína 7 | |
DE602006000877D1 (de) | Emulsionszusammensetzung | |
DE602007012648D1 (de) | Härtbare Zusammensetzung | |
DE602007004820D1 (de) | Härtbare Zusammensetzung | |
BRPI0810279A2 (pt) | "junta giratória" | |
FR2896414B1 (fr) | Composition cosmetique matifiante | |
DE602006011294D1 (de) | Klebstoffzusammensetzung | |
FR2885520B1 (fr) | Composition cosmetique | |
FR2885521B1 (fr) | Composition cosmetique | |
ZA200608611B (en) | Compounds and compositions as ppar modulators | |
ATE498659T1 (de) | Härtbare silikonzusammensetzung | |
FR2899582B1 (fr) | Composition cosmetique antirides | |
FR2885801B1 (fr) | Composition cosmetique | |
FR2899465B1 (fr) | Composition cosmetique antirides |